Stephen Raillard serves as Vice President, Chemical Development and Manufacturing. In this role, Dr. Raillard is responsible for chemical development activities in support of new product candidates and product platforms as well as leading chemical development and manufacturing activities in support of Kodiak’s drug substance portfolio. Dr. Raillard brings to Kodiak over twenty years of experience in building and leading global teams tasked with pharmaceutical research and development, process scale-up and commercial manufacturing. Most recently, Dr. Raillard was Executive Director of Chemical Development at XenoPort, Inc. In this role, he was responsible for developing the commercial manufacturing process for Gabapentin enacarbil (Tradename HORIZANT) and for commercial manufacturing campaigns. In addition, he was responsible for the development and manufacture of seven additional APIs in XenoPort’s portfolio, four of which entered clinical trials. Dr. Raillard was a core Chemistry Manufacturing and Controls (CMC) team member in due diligence discussions that led to licensing agreements with GSK and Astellas for Gabapentin enacarbil, Indivior for Arbaclofen Placarbil, and Dr. Reddy’s for XP23829, a monomethyl fumarate prodrug. Dr. Raillard has contributed to CMC filings and interactions with global regulatory authorities across the spectrum of drug discovery, development, and commercialization including pre-Investigational New Drug Applications, New Drug Applications, and post-approval commitments. Prior to joining Kodiak, Dr. Raillard held technical positions at Affmax Research Institute where, among other duties, he invented and reduced to practice methods enabling fast scale-up using solid-phase chemistry on custom high-load polymer resins. Dr. Raillard received his Ph.D. from the ETH Zürich in Switzerland followed by a post-doc at The Scripps Research Institute in La Jolla, CA.
Vice President, Chemical Development and Manufacturing